Status In progress
Process MTA
Topic area
  • Musculoskeletal
  • Therapeutic procedures

Project Team

Project lead Kate Moore

Email enquiries


Companies sponsors Swedish Orphan Biovitrium
Others Department of Health
  NHS England
  NHS Herts Valleys CCG (West)
  Welsh Government
Patient carer groups British Dupuytren’s Society
Professional groups British Association of Hand Therapists
  British Society for Surgery of the Hand
  Royal College of Nursing
  Royal College of Physicians


General commentators British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Orthopaedic Research UK


Key events during the development of the guidance:

Date Update
28 February 2017 Committee meeting: 6
06 February 2017 Appeal decision
27 January 2017 Following the committee discussion on 24 November 2016, the company has requested to submit a new value proposition for collagenase clostridium histolyticum for consideration by the appraisal committee. NICE has agreed to accept this. Therefore, we will not be releasing a document following the November meeting. The committee will consider this additional information from the company and continue its deliberations in in a part 2 (private) session on Tuesday 28 February 2017.
24 November 2016 Committee meeting: 5
04 November 2016 Following the publication of the appeal decision for the above appraisal, we have commissioned the NICE Decision Support Unit (DSU) to undertake further work to address the conclusions of the appeal panel. The DSU report will be shared with the committee members in advance of a committee meeting discussion in 24 November 2016. We will share the final specification of the work that is being commissioned in due course.
28 June 2016 Appeal decision
21 April 2016 An appeal hearing was held on 30 November 2015 for the above appraisal and the outcome of the appeal was discussed at NICE’s Guidance Executive in early 2016. Following this, further internal discussion is required before we are able to release the outcome of the appeal. Please accept our apologies for the delay, but we will endeavour to update you as soon as is possible.
30 November 2015 Appeal
16 September 2015 Following further consideration of this topic, the Committee has prepared a further FAD2, which supersedes the original FAD
04 August 2015 Committee meeting: 4
07 July 2015 Further to representation made by the company, the Final Appraisal Determination (FAD) for this appraisal was suspended. Errors in the Assessment Group model were identified and the company requested to submit further analyses for this appraisal. We have accepted this additional information which the Assessment Group is now reviewing. Therefore this information will be discussed at a further committee meeting, which has been scheduled for Tuesday 04 August 2015.
15 April 2015 The final appraisal determination for this appraisal is currently paused.
07 January 2015 Committee meeting: 3
14 October 2014 Committee meeting: 2
08 August 2014 Further to the below update on the 30 July 2014, the additional analyses will be discussed at a committee meeting on 14 October 2014.
30 July 2014 Following the meeting of the NICE technology appraisal committee on 15 July 2014 April the committee have requested that the assessment group provide additional analyses. No appraisal consultation document (ACD) will be issued at this stage. We will provide an update with the next steps in this appraisal once these are confirmed.
15 July 2014 Committee meeting: 1

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance